Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 451

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial

Open access
Liau, Linda M., Ashkan, Keyoumars, Brem, Steven, Campian, Jian L., Trusheim, John E., Iwamoto, Fabio M., Tran, David D., Ansstas, George, Cobbs, Charles S., Heth, Jason A., Salacz, Michael E., D’Andre, Stacy, Aiken, Robert D., Moshel, Yaron A., Nam, Joo Y., Pillainayagam, Clement P., Wagner, Stephanie A., Walter, Kevin A., Chaudhary, Rekha, Goldlust, Samuel A., Lee, Ian Y., Bota, Daniela A., Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J., Ewend, Matthew G., Khagi, Simon, Lovick, Darren S., Portnow, Jana, Kim, Lyndon, Loudon, William G., Martinez, Nina L., Thompson, Reid C., Avigan, David E., Fink, Karen L., Geoffroy, Francois J., Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M., Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P., Wu, Julian K., Dunbar, Erin M., Etame, Arnold B., Kesari, Santosh, Mathieu, David, Piccioni, David E., Baskin, David S., Lacroix, Michel, May, Sven-Axel, New, Pamela Z., Pluard, Timothy J., Toms, Steven A., Tse, Victor, Peak, Scott, Villano, John L., Battiste, James D., Mulholland, Paul J., Pearlman, Michael L., Petrecca, Kevin, Schulder, Michael, Prins, Robert M., Boynton, Alton L., Bosch, Marnix L.·2023·JAMA Oncology

Abstract

Importance: Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. Objective: To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma. Design, Setting, and Participants: This phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021. Interventions: The active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies. Main Outcomes and Measures: The primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials. Results: A total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after recurrence was 20.7% vs 9.6% and 11.1% vs 5.1%, respectively. Survival was improved in patients with nGBM with methylated MGMT receiving DCVax-L compared with external control patients (HR, 0.74; 98% CI, 0.55-1.00; P = .03). Conclusions and Relevance: In this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone. Trial Registration: ClinicalTrials.gov Identifier: NCT00045968

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2022.5370

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 451

Metadata

Authors
Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., Goldlust, S. A., Lee, I. Y., Bota, D. A., Elinzano, H., Grewal, J., Lillehei, K., Mikkelsen, T., Walbert, T., Abram, S., Brenner, A. J., Ewend, M. G., Khagi, S., Lovick, D. S., Portnow, J., Kim, L., Loudon, W. G., Martinez, N. L., Thompson, R. C., Avigan, D. E., Fink, K. L., Geoffroy, F. J., Giglio, P., Gligich, O., Krex, D., Lindhorst, S. M., Lutzky, J., Meisel, H.-J., Nadji-Ohl, M., Sanchin, L., Sloan, A., Taylor, L. P., Wu, J. K., Dunbar, E. M., Etame, A. B., Kesari, S., Mathieu, D., Piccioni, D. E., Baskin, D. S., Lacroix, M., May, S.-A., New, P. Z., Pluard, T. J., Toms, S. A., Tse, V., Peak, S., Villano, J. L., Battiste, J. D., Mulholland, P. J., Pearlman, M. L., Petrecca, K., Schulder, M., Prins, R. M., Boynton, A. L., & Bosch, M. L.
Venue
JAMA Oncology
Published
2023-01-01
Volume
9
Issue
1
Pages
112
ISSN
2374-2437 (ISSN-L)
OpenAlex
W4309183974
Cited by
451
References
41
FWCI
42.97
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2022.5370
The paper
Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., . . . Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2022.5370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.